Ancilia Biosciences offers bacterial therapeutics that address the microbiome's viral components.
Ancilia Biosciences has raised $10.1M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in April 2026.
Ancilia Biosciences's investors include National Science Foundation, Safar Partners, Metaplanet, Spacecadet Ventures, PsyMed Ventures.
Ancilia Biosciences is headquartered in New York, United States.
Ancilia Biosciences offers bacterial therapeutics that address the microbiome's viral components.
Ancilia Biosciences is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ancilia Biosciences — Funding & Investors." VCBacked, April 6, 2026, https://www.vcbacked.co/company/ancilia-biosciences. Accessed July 20, 2026.
VCBacked. (2026). Ancilia Biosciences — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/ancilia-biosciences
{{cite web |title=Ancilia Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/ancilia-biosciences |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated